Clinical Trial

CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL

Name: CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL — clinical trial record (NCT06445803)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This study examines the safety, tolerability and preliminary efficacy of anti-CD19 /CD22 CAR T cells (KQ-2002)manufactured on-site in adults with relapsed or refractory CD19+ B cell acute lymphoblastic leukemia or CD19+ B cell non Hodgkin lymphoma.

Trial Details

NCT Number	NCT06445803
Lead Sponsor	Rong Tao Collaborators: Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
Conditions	Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent
Enrollment	48 participants
Start Date	2024-05-31
Primary Completion	2026-10 (estimated)
Study Completion	2026-12 (estimated)
Updated on ClinicalTrials.gov	2024-06-06